Liver chirrosis

Reading File

Finding Sources

Searching PubMed

"liver cirrhosis"[MeSH Terms] AND management

Reading File

Loading Image

Reading File

I now have comprehensive, authoritative content from Goldman-Cecil Medicine and Robbins Pathology. I can now write a thorough answer.

Liver Cirrhosis

Definition

Cirrhosis is the diffuse transformation of the liver into regenerative parenchymal nodules surrounded by fibrous bands. It represents the end stage of any chronic liver disease and is characterized by disruption of the normal hepatic architecture, vascular distortion, and progressive loss of functional liver mass.

Robbins & Kumar Basic Pathology, p. 598
Goldman-Cecil Medicine, p. 1614

Normal vs. Cirrhotic Liver - gross and microscopic

Fig. 139-1: A = normal liver (smooth, homogeneous); B = normal sinusoidal architecture; C = cirrhotic liver (orange-tawny, nodular surface); D = regenerative nodules surrounded by fibrous tissue

Etiology / Causes

Major causes (globally):

Alcoholic liver disease
Non-alcoholic fatty liver disease (NAFLD/MASLD)
Chronic hepatitis B
Chronic hepatitis C (less common now due to effective antivirals)

Less common causes (<2% each):

Cholestatic/autoimmune: Primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis
Metabolic: Hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, glycogen storage diseases, porphyria
Mechanical obstruction: Biliary atresia, cystic fibrosis
Vascular: Budd-Chiari syndrome, veno-occlusive disease, right-sided heart failure
Drugs and toxins
Cryptogenic cirrhosis: no identifiable cause

Goldman-Cecil Medicine, p. 1615 (Table 139-1)

Pathogenesis

1. Hepatic Stellate Cell Activation

The central mechanism is activation of hepatic stellate cells (Ito cells / perisinusoidal cells), which reside in the space of Disse between hepatocytes and sinusoidal endothelial cells.

At rest: stellate cells are quiescent and store retinoids (vitamin A)
In response to injury: they lose vitamin A, proliferate, develop rough ER, and secrete extracellular matrix (collagen types I and III, sulfated proteoglycans, glycoproteins)
They transform into contractile myofibroblasts

2. Sinusoidal Capillarization

Normal hepatic sinusoids lack a basement membrane and have fenestrated endothelium (100-200 nm), permitting large molecules (up to 250,000 Da) to pass freely. Collagen deposition in the space of Disse leads to defenestration of sinusoidal endothelial cells ("capillarization"), reducing exchange between plasma and hepatocytes and narrowing sinusoidal diameter further.

3. Fibrosis and Nodule Formation

Progressive collagen deposition links portal tracts to each other (or to central veins), trapping regenerating hepatocyte clusters into nodules. The balance between fibrosis progression and regression (which can occur after disease cure or remission) dictates clinical outcome.

Goldman-Cecil Medicine, p. 1614-1615

Morphology

Gross: Liver surface shows bulging, irregularly sized regenerative nodules. Color may be tawny-orange (alcoholic) or dark (viral/other)
Micro: Rounded parenchymal nodules surrounded by fibrous septa (Masson trichrome stain highlights collagen in blue); ductular reactions (stemcell-derived ductlike structures) prominent
Micronodular cirrhosis: nodules <3 mm, typically alcoholic
Macronodular cirrhosis: nodules >3 mm, typically viral hepatitis
Regression features: thinner, denser-compacted scars that fragment over time

Robbins & Kumar, p. 598-599

Clinical Staging

Cirrhosis is classified into two prognostically distinct stages:

Stage	Definition	Key mechanism
Compensated	No decompensating event; often asymptomatic	Fibrosis/nodules without functional failure
Decompensated	Ascites, variceal hemorrhage, encephalopathy, or jaundice	Portal hypertension + liver insufficiency

About 40% of patients are asymptomatic until advanced disease. Early symptoms are nonspecific: anorexia, weight loss, weakness.

Pathophysiology of Complications

Portal Hypertension

Results from two mechanisms:

Increased sinusoidal resistance - fixed component (fibrosis/nodule compression) + functional component (active vasoconstriction from intrahepatic NO deficiency and enhanced vasoconstrictors)
Increased portal venous inflow - splanchnic arteriolar vasodilation driven by NO and other vasodilators produced in response to portal hypertension

Early: spleen enlarges and sequesters platelets (hypersplenism). Later: collateral vessels develop (portosystemic shunts).

Esophagogastric Varices

Develop in ~40% of advanced cirrhosis
Most clinically important consequence of portal hypertension
Risk of massive, potentially fatal hematemesis (especially with coagulopathy)

Ascites

~85% of ascites cases are due to cirrhotic portal hypertension
Fluid is a transudate: protein <3 g/dL, serum-to-ascites albumin gradient (SAAG) ≥1.1 g/dL

Hepatic Encephalopathy

Occurs at ~2-3% per year in cirrhotic patients
Spectrum: subclinical → grade 1 (sleep inversion, forgetfulness) → grade 2 (confusion, disorientation) → grade 3 (lethargy, profound disorientation) → grade 4 (coma)
Hallmark sign: asterixis (flapping tremor)
Characteristic breath: fetor hepaticus (sweet-smelling)
Pathogenesis: combined effect of portal hypertension (shunting of gut toxins, especially ammonia) + liver insufficiency

Spontaneous Bacterial Peritonitis (SBP)

~1/3 of cirrhotics admitted to hospital develop bacterial infection
Presenting features: fever, jaundice, abdominal pain, rebound tenderness - but up to 1/3 are initially asymptomatic
Can also present as encephalopathy, acute kidney injury, or shock

Hepatorenal Syndrome (HRS)

Prerenal kidney injury from maximal peripheral vasodilation + intense renal artery vasoconstriction + hormonal sodium/water retention
HRS-AKI (formerly Type 1): rapidly progressive, creatinine rise within 2 weeks - poor prognosis
HRS-non-AKI (formerly Type 2): slower, associated with diuretic-refractory ascites

Pulmonary Complications

Hepatopulmonary syndrome: intrapulmonary vascular shunting - presents with exertional dyspnea
Portopulmonary hypertension: elevated pulmonary arterial pressure

Hyperestrogenemia (males)

Impaired estrogen catabolism leads to:

Palmar erythema
Spider angiomas (skin)
Gynecomastia, testicular atrophy

Prognostic Scoring

Child-Pugh Score

Incorporates: bilirubin, albumin, PT/INR, ascites, encephalopathy

Classes A/B/C - used for surgical risk and prognosis

MELD Score

MELD = [0.957 × ln(creatinine) + 0.378 × ln(bilirubin) + 1.12 × ln(INR) + 0.643] × 10

MELD-Na: If MELD ≥12, adjusted with serum sodium: MELD-Na = MELD(0) + 1.32 × (137 - Na) - [0.033 × MELD(i) × (137 - Na)]

MELD-Na is the primary tool for organ allocation on liver transplant waitlists.

Goldman-Cecil Medicine, p. 1615 (Table 139-2)

Management Overview

Problem	Treatment
Underlying cause	Antivirals (HBV/HCV), alcohol abstinence, weight loss (NAFLD)
Portal hypertension (prophylaxis)	Non-selective beta-blockers (propranolol, nadolol, carvedilol)
Varices - primary/secondary prophylaxis	Beta-blockers ± endoscopic band ligation
Acute variceal bleeding	IV octreotide/terlipressin, urgent endoscopy (band ligation), TIPS if refractory
Ascites	Salt restriction, spironolactone ± furosemide; paracentesis for refractory
SBP	Cefotaxime/ceftriaxone; prophylaxis with norfloxacin in high-risk patients
Hepatic encephalopathy	Lactulose (first-line), rifaximin (second-line/maintenance); identify precipitants
HRS-AKI	Albumin + vasoconstrictors (terlipressin preferred; norepinephrine); treat precipitants
End-stage disease	Liver transplantation (only definitive treatment)

Recent evidence note: A 2025 meta-analysis (PMID 40597728) on timing of endoscopy in acute variceal bleeding confirms early endoscopy (within 12 hours) is beneficial in cirrhotic patients - aligning with current guidelines.

Key Points to Remember

Cirrhosis is not a specific diagnosis - it is a morphologic endpoint of many diseases with variable prognosis
Regression is possible - fibrosis can remodel if the underlying cause is removed (e.g., cured hepatitis C, alcohol abstinence)
The two pillars of morbidity are portal hypertension and liver insufficiency
Compensated cirrhosis may be clinically silent for years; decompensation markedly worsens prognosis (1-year mortality ~20-57%)
HCC surveillance (ultrasound every 6 months ± AFP) is indicated in all cirrhotic patients

Sources: Robbins & Kumar Basic Pathology, p. 597-600; Goldman-Cecil Medicine, pp. 1614-1619

This is a shared conversation. Sign in to Orris to start your own chat.